Relationship between serum cell division cyclin 42 and clinicopathological characteristics and prognosis of AFP-negative hepatocellular carcinoma patients

doi:10.3969/j.issn.1673-8640.2025.03.010

Abstract

Abstract:

Objective To investigate the relationship between serum cell division cyclin 42（CDC42）and clinicopathological characteristics and prognosis of alpha-fetoprotein （AFP）-negative hepatocellular carcinoma （HCC） patients. Methods A total of 120 AFP-negative HCC patients （AFP-HCC group） and 40 healthy subjects （healthy control group） were enrolled from Hai'an People's Hospital from January 2015 to December 2020. The clinical data were collected，and serum CDC42 levels were determined. Kaplan-Meier survival curve was used to analyze the survival of AFP-negative HCC patients，and Cox risk proportional regression analysis was used to evaluate the influencing factors of death in AFP-negative HCC patients. Receiver operating characteristic（ROC） curve was used to evaluate the efficacy of CDC42 in determining death in AFP-negative HCC patients. Results The serum CDC42 level in AFP-HCC group was higher than that in healthy control group（P<0.001）. There was statistical significance in serum CDC42 levels among AFP-negative HCC patients at different stages，T stages，N stages and M stages（P<0.001）. The overall survival rate of low CDC42 group was higher than that of high CDC42 group（Log-rank χ2=8.71，P<0.001）. CDC42 and Stage stage were independent risk factors for prognosis（death）in AFP-negative HCC patients [hazard ratios（HR）were 1.274 and 3.666，95% confidence intervals（CI）were 1.12-1.47 and 1.70-7.92]. The area under curve of CDC42 to determine the death of AFP-negative HCC patients was 0.723，the optimal cut-off value was 1.092 ng·mL^-1，the sensitivity was 75.0%，and the specificity was 68.3%. Conclusions CDC42 is related to the clinicopathological characteristics of HCC，and may be used as a prognostic indicator for AFP-negative HCC patients.

Key words: Cell division cyclin 42, Alpha-fetoprotein, Hepatocellular carcinoma, Prognosis

CLC Number:

R446.1

WANG Xiaolong, CHEN Yuanbin. Relationship between serum cell division cyclin 42 and clinicopathological characteristics and prognosis of AFP-negative hepatocellular carcinoma patients[J]. Laboratory Medicine, 2025, 40(3): 259-263.

Figures/Tables 5

References 22

[1]	GAO T, ZHI J, MU C, et al. One-step detection for two serological biomarker species to improve the diagnostic accuracy of hepatocellular carcinoma[J]. Talanta, 2018, 178:89-93. DOI PMID
[2]	LUO P, WU S, YU Y, et al. Current status and perspective biomarkers in AFP negative HCC:towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2):599-603.
[3]	ILYAS S I, WANG J, EL-KHOUEIRY A B. Liver cancer immunity[J]. Hepatology, 2021, 73 Suppl 1(Suppl 1):86-103.
[4]	FENG M, PAN Y, KONG R, et al. Therapy of primary liver cancer[J]. Innovation(Camb), 2020, 1(2):100032.
[5]	CHEN J, NIU C, YANG N, et al. Biomarker discovery and application-an opportunity to resolve the challenge of liver cancer diagnosis and treatment[J]. Pharmacol Res, 2023, 189:106674.
[6]	MANSOURI V, RAZZAGHI M, NIKZAMIR A, et al. Assessment of liver cancer biomarkers[J]. Gastroenterol Hepatol Bed Bench, 2020, 13(Suppl1):S29-S39.
[7]	宋振宇, 杨丽超, 廖舟翔, 等. Lnc85通过调节CDC42的表达促进肝癌细胞增殖[J]. 广西医科大学学报, 2024, 41(2):186-192.
[8]	雒博晗, 韩国宏. 《2023年美国肝病学会实践指南:肝硬化门静脉高压和静脉曲张的风险分层及管理》摘译[J]. 临床肝胆病杂志, 2024, 40(1):33-36.
[9]	童磊, 陈正岗, 郑海波, 等. 细胞分裂周期蛋白42基因在肿瘤中的研究进展[J]. 中国临床医生杂志, 2024, 52(4):386-389.
[10]	慕家宁, 袁文清, 陆洲, 等. CDC42在舌鳞状细胞癌中的表达及其对细胞增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2023, 21(3):209-217.
[11]	王蕾, 刘宪, 张燕茹, 等. HK2通过Akt1/p-Akt1上调CDC42表达促进宫颈癌细胞迁移和侵袭[J]. 现代肿瘤医学, 2022, 30(11):1931-1936.
[12]	HIRSCH D S, WU W J. CDC42:an effector and regulator of ErbB1 as a strategic target in breast cancer therapy[J]. Expert Rev Anticancer Ther, 2007, 7(2):147-157.
[13]	DU D S, YANG X Z, WANG Q, et al. Effects of CDC42 on the proliferation and invasion of gastric cancer cells[J]. Mol Med Rep, 2016, 13(1):550-554.
[14]	SPEL L, ZAFFALON L, HOU C, et al. CDC42 regulates PYRIN inflammasome assembly[J]. Cell Rep, 2022, 41(7):111636.
[15]	MURPHY N P, BINTI A M A, MOTT H R, et al. Molecular subversion of CDC42 signalling in cancer[J]. Biochem Soc Trans, 2021, 49(3):1425-1442.
[16]	MURPHY N P, MOTT H R, OWEN D. Progress in the therapeutic inhibition of CDC42 signalling[J]. Biochem Soc Trans, 2021, 49(3):1443-1456.
[17]	AGUILAR B J, ZHOU H, LU Q. Cdc42 signaling pathway inhibition as a therapeutic target in ras- related cancers[J]. Curr Med Chem, 2017, 24(32):3485-3507. DOI PMID
[18]	YE H, ZHANG Y, GENG L, et al. CDC42 expression in cervical cancer and its effects on cervical tumor invasion and migration[J]. Int J Oncol, 2015, 46(2):757-763. DOI PMID
[19]	ZHANG B, ZHANG J, XIA L, et al. Inhibition of CDC42 reduces macrophage recruitment and suppresses lung tumorigenesis in vivo[J]. J Recept Signal Transduct Res, 2021, 41(5):504-510.
[20]	张瑶瑶, 雷芯, 戴光荣. AFP阴性肝癌相关血清学标志物的研究进展[J]. 肝脏, 2023, 28(9):1112-1115.
[21]	方志豪, 李青, 陈慧丽, 等. 抗-PTCH1自身抗体在甲胎蛋白阴性肝癌中的诊断价值[J]. 中国卫生检验杂志, 2023, 33(7):774-778.
[22]	胡良峰, 吴敏解, 张丽红. 外周血淋巴细胞与单核细胞比值联合CA125对甲胎蛋白阴性原发性肝癌的诊断价值[J]. 中国卫生检验杂志, 2022, 32(7):832-835.

病理特征	例数	CDC42/（ng·mL^-1）
Stage分期	120
Ⅰ期	22	0.18（0.10，0.30）
Ⅱ期	39	0.78（0.52，1.46）
Ⅲ期	29	1.45（0.74，2.45）
Ⅳ期	36	2.64（1.37，5.06）
H值		8.854
P值		<0.001
T分期	120
T1~T2期	63	0.73（0.20，1.41）
T3~T4期	57	1.70（0.82，3.88）
H值		10.323
P值		<0.001
N分期	120
N0期	94	0.76（0.48，1.45）
N1~3期	26	2.51（1.30，5.06）
H值		12.381
P值		<0.001
M分期	120
M0期	107	0.80（0.54，1.52）
M1期	13	2.56（0.10，5.57）
H值		12.887
P值		<0.001

病理特征	例数	CDC42/（ng·mL^-1）
Stage分期	120
Ⅰ期	22	0.18（0.10，0.30）
Ⅱ期	39	0.78（0.52，1.46）
Ⅲ期	29	1.45（0.74，2.45）
Ⅳ期	36	2.64（1.37，5.06）
H值		8.854
P值		<0.001
T分期	120
T1~T2期	63	0.73（0.20，1.41）
T3~T4期	57	1.70（0.82，3.88）
H值		10.323
P值		<0.001
N分期	120
N0期	94	0.76（0.48，1.45）
N1~3期	26	2.51（1.30，5.06）
H值		12.381
P值		<0.001
M分期	120
M0期	107	0.80（0.54，1.52）
M1期	13	2.56（0.10，5.57）
H值		12.887
P值		<0.001

项目	单因素Cox回归分析		多因素Cox回归分析
项目	HR值（95%CI）	P值	HR值（95%CI）	P值
年龄	1.01（0.98~1.04）	0.459
性别	1.41（0.82~2.42）	0.212
BMI	1.21（0.74~3.37）	0.359
T分期	3.14（1.80~5.47）	<0.001	0.74（0.36~1.51）	0.401
N分期	5.17（2.96~9.03）	<0.001	0.54（0.17~1.78）	0.315
M分期	5.21（2.59~10.45）	<0.001	0.96（0.37~2.52）	0.940
Stage分期	2.99（2.15~4.15）	<0.001	3.67（1.70~7.92）	0.001
CDC42	1.46（1.31~1.63）	<0.001	1.27（1.12~1.47）	0.001

项目	单因素Cox回归分析		多因素Cox回归分析
项目	HR值（95%CI）	P值	HR值（95%CI）	P值
年龄	1.01（0.98~1.04）	0.459
性别	1.41（0.82~2.42）	0.212
BMI	1.21（0.74~3.37）	0.359
T分期	3.14（1.80~5.47）	<0.001	0.74（0.36~1.51）	0.401
N分期	5.17（2.96~9.03）	<0.001	0.54（0.17~1.78）	0.315
M分期	5.21（2.59~10.45）	<0.001	0.96（0.37~2.52）	0.940
Stage分期	2.99（2.15~4.15）	<0.001	3.67（1.70~7.92）	0.001
CDC42	1.46（1.31~1.63）	<0.001	1.27（1.12~1.47）	0.001